GlassScriptPhysician profile
Annelise Bowman
NPI 1225871148
$507.73
in general payments reported to CMS, 2019-2025
18 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $34.99 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $78.35 | 2025 | Auvelity |
| Viiv Healthcare Company | $60.07 | 2025 | Rukobia, Apretude |
| Antares Pharma, INC. | $54.18 | 2024-2025 | Xyosted |
| Abbvie INC. | $51.45 | 2025 | |
| Merck Sharp & Dohme LLC | $45.74 | 2025 | Zerbaxa, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.64 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.54 | 2025 | Rexulti |
| Novo Nordisk INC | $19.29 | 2025 | Ozempic, Rybelsus |
| Collegium Pharmaceutical, INC. | $17.15 | 2024 | Xtampza |
| Pfizer INC. | $17.06 | 2025 | |
| Abiomed | $16.97 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.73 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $16.28 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $15.90 | 2025 | Rexulti |
| Seqirus USA INC | $15.09 | 2025 | Fluad, Flucelvax |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $14.57 | 2025 | Rexulti |
| Lilly USA, LLC | $13.82 | 2025 | Mounjaro, Zepbound |
| Dynavax Technologies Corporation | $11.90 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annelise Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.